How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,329 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

9001. Optimization of Pulmonary Rehabilitation Programmes: the OPTION Study

for each subject. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 40 Years and older (Adult, Older Adult (...) More Information Go to Publications of Results: Other Publications: TechnoGym. Wellness System. [cited 2006 September 25]; Available from: http://www.technogymusa.com/_vti_g7_plsystem.aspx?rpstry=11902_ Beck, A.T., et al., Cognitive Therapy of Depression. 1979, New York, NY: Guilford Press. Strauss, E., E.M. Sherman, and O. Spreen, A compendium of neuropsychological tests: administration, norms, and commentary. 3rd ed. 2006, New-York, NY: Oxford University Press. Ware, J.E., M. Kosinski, and S.D

2013 Clinical Trials

9002. Heart Attack Prevention Programme for You (HAPPY) London

people make the necessary changes in their lifestyle to reduce the risk of heart attacks and strokes. Condition or disease Intervention/treatment Phase Cardiovascular Disease Behavioral: Electronic coaching plus standard care Not Applicable Detailed Description: Heart Attack Prevention Programme for You London (HAPPY London) will be conducted as a randomised controlled trial comparing the use of tailored e-coaching in addition to the standard of care vs. standard care alone. Standard care is defined (...) a healthier lifestyle as a primary prevention tool to reduce the CV risk and improve the quality of life in asymptomatic individuals with intermediate to high 10 year CV risk. Other questions that we aim to answer are: Is computer-tailored e-coaching cost-effective in the short-term (clinical trial period) and during the long-term (decision analysis modelling) What are the associations of personality traits, economic preferences, and sociocultural factors with the achieved lifestyle modifications

2013 Clinical Trials

9003. An Interactive Preventive Health Record to Increase Colorectal Cancer Screening

, links clicked. In addition to elucidating patients' uptake of intervention components, these data can indicate engagement for dose-response analyses or be examined as potential mediators. For Phase II, this data will allow us to assess the timing of intervention reminders to make a decision about what frequency is most appropriate so that we can modify before we begin the feasibility study (phase III). Psychosocial Constructs [ Time Frame: Phase II: Baseline, 3 months, and 9 months post (...) , these data can indicate engagement for dose-response analyses or be examined as potential mediators. For Phase II, this data will allow us to assess the timing of intervention reminders to make a decision about what frequency is most appropriate so that we can modify before we begin the feasibility study (phase III). Psychosocial Constructs [ Time Frame: Phase III: Baseline and 9 months post intervention ] Scales (e.g. Decisional conflict, intentions , self-efficacy, perceived susceptibility, worry, etc

2013 Clinical Trials

9004. GSK2339345 Hypertussive Challenge Study

occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization (...) Using an Aqueous Droplet Inhaler Study Start Date : November 2013 Actual Primary Completion Date : October 2014 Actual Study Completion Date : October 2014 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Part A Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB. Drug

2013 Clinical Trials

9005. Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

Actual Study Completion Date : February 2, 2012 Resource links provided by the National Library of Medicine related topics: related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Lomustine + Temozolomide + Thalidomide Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily. Drug: Lomustine Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29 (...) . Other Names: CCNU CeeNU Drug: Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Other Name: Temodar Drug: Thalidomide 200 mg/m^2 by mouth daily. Other Name: Thalomid Outcome Measures Go to Primary Outcome Measures : Maximum tolerated dose (MTD) [ Time Frame: 1 cycle (8 weeks) of therapy ] Secondary Outcome Measures : Objective (CR+PR) response rate at the MTD [ Time Frame: 1 cycle (8 weeks) of therapy ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing

2013 Clinical Trials

9006. The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors

months ] Proportion of participants who complete all 3-month online and in-clinic assessments. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility (...) prevention in African American breast cancer survivors, nor evaluated the use of frequent self-weighing as a self-regulation strategy. Regular self-weighing has been effectively used as an approach for weight maintenance that helps individuals monitor daily weight fluctuations and make small changes in energy balance behaviors. Given that the frequency of self-weighing among breast cancer survivors is unknown, and the importance of self-regulation behaviors for weight maintenance is well established

2013 Clinical Trials

9007. Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 64 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: English speaking Age 18-64 Competent to understand and make medical choices independently Exclusion Criteria: Currently or previously seen by a CMM pharmacist Contacts and Locations Go to Information from the National Library of Medicine To learn (...) With Antipsychotic Medications? Study Start Date : February 2010 Actual Primary Completion Date : February 2012 Actual Study Completion Date : February 2012 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Extended Treatment Group Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication

2013 Clinical Trials

9008. PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer

with substantial morbidity. A pathological complete response (pCR) after nCRT is seen in 28-34% of patients. Pathological non-responders (pNR) most probably do not benefit from nCRT but are exposed to its toxicity and delay from surgical therapy inevitably occurs in this group. Early identification of non-responders during nCRT would allow individualized decision making in continuation or discontinuation of nCRT. Furthermore, a tool is desirable to accurately assess the treatment response after nCRT (...) . At M.D. Anderson Cancer Center biopsy and blood samples will be collected for all patients. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility

2013 Clinical Trials

9009. Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

(Week 18). Number of Participants Hospitalized [ Time Frame: Baseline (Visit 2) to end of followup (Week 18) ] Number (%) of participants with at least one hospitalization between Baseline (Visit 2) and end of follow up (Week 18). Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you (...) A, vitamin E or tocopherols,vitamins D or K, n-acetylcysteine, glutathione, CoQ10, other over-the-counter antioxidant) for the duration of the study Use of vitamins (other than control vitamin) or antioxidants within 4 weeks prior to randomization Daily use of > 2 cans of Boost or Pulmocare dietary supplement formulas Known hypersensitivity to oral AquADEKs® For women of child bearing potential: positive pregnancy test at Visit 1 or at Visit 2, or lactating or unwilling to practice a medically acceptable

2013 Clinical Trials

9010. Nitisinone for Type 1B Oculocutaneous Albinism

by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Eye Institute (NEI) ) Study Details Study Description Go to Brief Summary: Background: - Oculocutaneous albinism, type 1B (OCA1B) is a genetic disease caused by problems in the gene that makes tyrosine. Tyrosine is an amino acid needed to produce pigment in the skin, hair, and eyes. People with OCA1B have pale skin, white hair, and light-colored eyes. Pigment in the back of the eye helps vision, so people with OCA-1B often (...) eight outpatient visits, each about 3 months apart. Each visit will require 1 to 2 days of testing. Participants will be screened with a physical exam, eye exam, and medical history. They will have additional vision and neurological tests. They will be tested to see how their brain and retinas respond to light. They will also take hair and blood samples, and answer questions about diet. Participants will receive the study drug. They will take one pill a day for 1 year. They will keep track

2013 Clinical Trials

9011. Development of a Metabolic Assessment Tool for Chronic Kidney Disease

they take the capsules after their last meal of the day and before bed each evening. Study personnel contacted subjects throughout the course of the study by phone and/or e-mail to make sure that there were no adverse effects from the fish oil and to ensure compliance. Subjects were instructed to record their diets through 24-hour dietary recalls before the baseline blood draw, and at 3 additional time points throughout the study. Immediately after blood collection, the researchers separated the red (...) Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria

2013 Clinical Trials

9012. Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes

and decision aid. This tool, which is an iPad application, draws the patient in by showing them their personal risk and medication information derived from baseline labs and self-reported survey data. The tool encourages interaction by providing choices of materials to view, using audio-visual elements and incorporating a goal-setting process for developing self-management action steps and questions to discuss with their doctor at their next clinic visit. Ongoing weekly contact between the Veterans (...) patients with poor glycemic control. Such models are important complements to provision of care by formal health care providers as they provide sustained, flexible between-visit support. Peer supporters and coaches can be trained in effective behavioral approaches to support other Veterans' self-management behaviors. Such supporters, however, necessarily lack the content expertise to help Veterans make informed treatment decisions and set health goals with their health care providers. Accordingly

2013 Clinical Trials

9013. Study of DA-9801 to Treat Diabetic Neuropathy

from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy (...) disease not in remission for 5 years or more that has been medically or surgically treated without evidence of metastases Presence of one or more medical conditions, as determined by medical history, which seriously compromises the subject's ability to complete the study, including history of poor adherence with medical treatment, renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this study

2013 Clinical Trials

9014. The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.

to assessing physical and psychosocial symptoms, establishing goals of care, assisting decision making regarding treatment, and coordinating care on the basis of the individual needs of the patients. The doctor expert in palliative care, with regular visits in the experimental arm, must be a physician dedicated full time to palliative care, that can directly prescribe drugs and other interventions, and with a particular attention to physical, psychological, and spiritual needs. Palliative care doctor must (...) : 24 months ] The impact of families satisfaction about care will be evaluated by an Italian version of FAMCARE questionnaire. Overall survival (OS) [ Time Frame: 24 months ] It is the time from the date of randomization to the date of death due to any cause. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn

2013 Clinical Trials

9015. Vibratory Therapy for Patients With Chronic Low Back Pain

the standing position in the region previously marked on the equipment , so that the support base was identical for all volunteers . Also , samples were collected at rest , followed by consecutive flexion-extension of the trunk . Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor (...) Reabilitação Sensorio Motora Investigators Layout table for investigator information Principal Investigator: Djenifer Q Souza, Therapy University of Vale of Paraiba More Information Go to Additional Information: Publications: AHRENS, C.; SCHILTENWOLF, M.; WANG, H. Health-related quality of life (SF-36) inchronic low back pain and comorbid depression. Schmerz, v. 24, n. 3, p. 251-256, 2010. BASSANI, E. et al. Avaliação da ativação neuromuscular em indivíduos com escoliose através da eletromiografia de

2013 Clinical Trials

9016. Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

blockade on the host immune system [ Time Frame: Up to 4 months ] Measured via a series of correlative laboratory studies using cancer tumor tissue and peripheral blood mononuclear cells. Secondary Outcome Measures : Progression-free survival [ Time Frame: Up to 1 year ] Overall survival [ Time Frame: Up to 1 year ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members (...) Official Title: A Pilot Study of Beta-Blockers in Patients With Advanced Cancer Actual Study Start Date : January 21, 2014 Estimated Primary Completion Date : December 31, 2019 Estimated Study Completion Date : December 31, 2019 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment (propranolol hydrochloride) Patients receive propranolol hydrochloride PO BID for 4 months

2013 Clinical Trials

9017. Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels

Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 55 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All (...) 18.5 to 25 kg/m^2 Willingness and ability to give consent Willingness to make time commitment for the study EXCLUSION CRITERIA Progressive or unstable disease of any body system including cardiovascular, pulmonary, gastrointestinal, central nervous system, psychiatric, endocrine, hematologic, renal or immunologic disorders Known acute or chronic inflammatory disease ( e.g. rheumatoid arthritis, systemic lupus erythematosus, hepatitis) Elevated C-reactive protein (CRP) level > 3.0 mg/L Elevated

2013 Clinical Trials

9018. Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Actual Primary Completion Date : August 26, 2014 Actual Study Completion Date : September 6, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: E/C/F/TAF (Double-Blind Phase) E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks Drug: E/C/F/TAF 150/150/200/10 mg FDC tablet administered orally once daily Other Name: Genvoya® Drug: E/C/F/TDF Placebo Tablet administered orally once daily Active Comparator: E/C/F (...) from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers

2013 Clinical Trials

9019. Smokers' Response to Nicotine Dependence Genotyping

Knowledge of Genetic Contributions to Smoking at 2, 6, and 10 Weeks after Genotyping Results [ Time Frame: 2, 6, and 10 weeks after genotyping results ] Knowledge Test of Genetics & Smoking Investigator Developed. 20 items; correct items are summed. Scores 0-20. Higher scores indicate more knowledge. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about (...) ; pregnant, or currently enrolled in another smoking research study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01780038 Locations Layout table for location information United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska

2013 Clinical Trials

9020. IMPACT

2013 Estimated Primary Completion Date : October 2015 Estimated Study Completion Date : October 2015 Groups and Cohorts Go to Group/Cohort Intervention/treatment Primary care patients Primary care patients who are members of UAIHC. Other: Integrative medicine primary care model An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine. Outcome Measures Go to Primary Outcome Measures : Total healthcare costs from the payer's perspective—total paid costs (...) communication style, shared decision-making, trust in the practitioner, perceived practitioner empathy, perceived health partnership, and demographic information (CAHPS - AHRQ, 2012; ACES - Safran et al, 1998); CARE - Mercer, et al, 2004). Provider Experiences (Fidelity) [ Time Frame: Monthly for the first 6 months, then each 3 months for the rest of the first year, then every 6 months ] Composite: Team Climate Inventory Short Version (TCI - Anderson & West, 1995; Loo & Loewen, 2002). Additional items were

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>